Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F22%3A00076482" target="_blank" >RIV/00159816:_____/22:00076482 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/22:00076482 RIV/00064203:_____/22:10444556 RIV/00216208:11130/22:10444556 RIV/00216224:14110/22:00126164
Result on the web
<a href="https://ascopubs.org/doi/pdf/10.1200/PO.21.00525?role=tab" target="_blank" >https://ascopubs.org/doi/pdf/10.1200/PO.21.00525?role=tab</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1200/PO.21.00525" target="_blank" >10.1200/PO.21.00525</a>

Result language
angličtina
Original language name
Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing
Original language description
There are about 100 new children presenting with anaplastic large cell lymphoma (ALCL) in the United States and Europe each year. Among these patients, approximately 90% harbor ALK gene rearrangements, with NPM1-ALK being the most prevalent.1 Despite the use of several different intensive chemotherapy approaches, about one third of patients will experience a relapse of the disease.2 In relapsed patients, multiple therapeutic strategies can be considered. The frequency of ALK gene rearrangements in ALCL and the success of ALK inhibitors in other cancer types3 led to early use of tyrosine kinase inhibitors (TKIs) in patients with ALK gene rearrangement-positive ALCL (ALK-positive ALCL). Crizotinib, which showed to be not only well-tolerated in the pediatric population but also to have high response rates,4 is already approved for relapsed ALCL in children and young adults.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)